Literature DB >> 8093107

Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes.

B Yu1, S Pugazhenthi, R L Khandelwal.   

Abstract

The effects of glucose and glucagon on the anti-gluconeogenic action of metformin were investigated in normal and diabetic hepatocytes. Glucose production from lactate was elevated by 88% in hepatocytes from fasted normal rats compared with hepatocytes from fed animals. Diabetes caused 3.5- and 2.1-fold increases in hepatic gluconeogenesis under fasting and fed conditions, respectively. Metformin (250 microM) suppressed glucose production by 37% in normal and by 30% in diabetic hepatocytes from fed rats. This drug was more effective (up to 67%) with increasing concentrations of glucose in the medium. Potentiation by metformin of insulin action on gluconeogenesis was elevated significantly (P < 0.01 to 0.001) by glucose in vitro. Metformin (75-250 microM) also counteracted the effects of glucagon at optimal concentrations in normal (32-68%) as well as diabetic (8-46%) hepatocytes. The findings of this study indicate that (i) the anti-gluconeogenic effect of metformin is enhanced by glucose in vivo and in vitro; and (ii) the suppression of glucagon-induced gluconeogenesis by metformin could play a role in its glucose-lowering effects in diabetic conditions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8093107     DOI: 10.1016/0006-2952(94)90365-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Locating the source of hyperglycemia: liver versus muscle.

Authors:  Haoyong Yu; Dequan Zhou; Weiping Jia; ZengKui Guo
Journal:  J Diabetes       Date:  2012-03       Impact factor: 4.006

2.  Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia.

Authors:  S D Mittelman; Y Y Fu; K Rebrin; G Steil; R N Bergman
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

3.  Insulin action on protein phosphatase-1 activation is enhanced by the antidiabetic agent pioglitazone in cultured diabetic hepatocytes.

Authors:  S Pugazhenthi; R L Khandelwal
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

Review 4.  The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.

Authors:  N F Wiernsperger; C J Bailey
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Direct regulation of glucose and not insulin on hepatic hexose-6-phosphate dehydrogenase and 11β-hydroxysteroid dehydrogenase type 1.

Authors:  Zheng Fan; Hongwei Du; Ming Zhang; Zhaojie Meng; Li Chen; Yanjun Liu
Journal:  Mol Cell Endocrinol       Date:  2010-12-14       Impact factor: 4.102

6.  New Insight Into Metformin Action: Regulation of ChREBP and FOXO1 Activities in Endothelial Cells.

Authors:  Xiaoyu Li; Karen L Kover; Daniel P Heruth; Dara J Watkins; Wayne V Moore; Kathyrin Jackson; Mengwei Zang; Mark A Clements; Yun Yan
Journal:  Mol Endocrinol       Date:  2015-07-06

Review 7.  Molecular mechanism of action of metformin: old or new insights?

Authors:  Graham Rena; Ewan R Pearson; Kei Sakamoto
Journal:  Diabetologia       Date:  2013-07-09       Impact factor: 10.122

8.  Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP.

Authors:  Russell A Miller; Qingwei Chu; Jianxin Xie; Marc Foretz; Benoit Viollet; Morris J Birnbaum
Journal:  Nature       Date:  2013-01-06       Impact factor: 49.962

Review 9.  Metformin: A Prospective Alternative for the Treatment of Chronic Pain.

Authors:  Guadalupe Del Carmen Baeza-Flores; Crystell Guadalupe Guzmán-Priego; Leonor Ivonne Parra-Flores; Janet Murbartián; Jorge Elías Torres-López; Vinicio Granados-Soto
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

10.  AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B.

Authors:  M Johanns; Y-C Lai; M-F Hsu; R Jacobs; D Vertommen; J Van Sande; J E Dumont; A Woods; D Carling; L Hue; B Viollet; M Foretz; M H Rider
Journal:  Nat Commun       Date:  2016-03-08       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.